iRhythm Technologies, Inc. — FY 2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; audited annual results, with unaudited fourth-quarter data. The filing identifies the registrant as iRhythm Technologies, Inc. (not “iRhythm Holdings, Inc.”). Filed March 31, 2017.
Business context
iRhythm is a commercial-stage digital healthcare company whose primary product is the ZIO Service: a wearable ECG patch used for continuous monitoring for up to 14 days, with cloud-based analysis and a report reviewed by cardiac technicians. Revenue is substantially from U.S. ZIO Service sales. The company reported more than 700,000 patients served and approximately 290 million U.S. insured lives with policies covering reimbursement as of year-end 2016.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 | Change |
|---|---|---|---|
| Revenue | $64.1 million | $36.1 million | +77% |
| Cost of revenue | $20.9 million | $14.7 million | +42% |
| Gross profit / margin | $43.2 million / 67% | $21.4 million / 59% | Margin +8 percentage points |
| Operating expenses | $58.8 million | $43.1 million | +36% |
| Operating loss | $(15.6) million | $(21.6) million | Loss narrowed |
| Net loss | $(20.9) million | $(22.8) million | Loss narrowed 8% |
| Operating cash flow | $(16.7) million | $(18.0) million | Cash use decreased |
FY 2016 fourth-quarter revenue was $18.7 million, gross profit was $12.9 million, and net loss was $6.3 million. Gross-margin improvement reflected manufacturing efficiencies, lower technician labor per device, greater fixed-cost absorption, and improved payer/customer mix. SG&A rose 41% to $51.6 million, principally from staffing, professional services, facilities, and bad-debt expense. R&D was $7.2 million, up 13%.
At year-end, cash and cash equivalents were $51.6 million, short-term investments $54.4 million, and long-term investments $11.0 million, or approximately $117.0 million combined. Working capital was $105.4 million. Debt was $32.2 million on the balance sheet; the filing separately reports $33.2 million of principal and interest outstanding. Contractual debt payments, including interest, totaled $46.3 million. Accumulated deficit was $127.2 million.
Material changes versus prior year
- Revenue grew $27.9 million: management attributed $19.7 million to higher service volume and $8.3 million to increased contracted rates.
- Gross margin rose from 59% to 67%, while operating expenses grew substantially, mainly from expansion of the sales and operating infrastructure.
- The October 2016 IPO generated approximately $110.7 million net proceeds. Preferred shares converted into common stock; year-end cash and investments increased materially.
- Third-party payors accounted for 74% of revenue, versus 62% in 2015; institutional customers accounted for 26%, versus 38%. Federal government agencies represented approximately 40% of revenue.
- Investing cash outflow rose to $68.2 million, primarily from $65.4 million of investment purchases; this was largely a deployment of IPO proceeds rather than operating investment alone.
Outlook, commentary, and risks
- Management expects revenue growth through broader adoption, more payer contracts, sales-force expansion, additional clinical use cases, and product development. It also expects continued operating losses and higher absolute R&D, sales and marketing, and public-company costs; the filing gives no quantified revenue or earnings guidance.
- About 17% of 2016 revenue was recognized only when payment was received or payment notification was received because reimbursement could not be reasonably estimated. Collections, denials, contractual allowances, bad debt, and the timing of payer payments are significant uncertainties.
- Pharmakon debt bears fixed interest of 9.5%; revenue covenant testing begins in June 2017. Debt is secured by substantially all assets and includes liquidity, revenue, and other covenants. A default could accelerate repayment; the agreement also provides a change-of-control payment option.
- Key business risks include reliance on the ZIO Service as the principal product, reimbursement-rate or coverage changes, physician adoption, competition, scaling manufacturing and service operations, dependence on certain single-source suppliers, and regulatory, privacy, cybersecurity, and product-liability exposure.
- The company reported no material litigation and no material change in internal control over financial reporting during the fourth quarter. The audit opinion was unqualified. Management’s internal-control assessment and auditor attestation were not included under the applicable newly public company/emerging-growth-company exemptions.
Important facts for investors to verify
- Whether revenue growth and gross-margin gains continue, and how much results depend on contracted payer rates versus volume.
- Receivables, contractual and doubtful-account allowances, collection experience, and the portion of revenue still recognized on a cash/notification basis.
- Compliance with the Pharmakon revenue and liquidity covenants beginning in 2017, debt service requirements, and remaining borrowing availability under the SVB line.
- Whether payer coverage and reimbursement remain intact as healthcare policy and Medicare payment rules change.
- Sales-force productivity, service capacity, quality-control remediation, and continuity of supply from critical single-source vendors.
- Potential dilution from outstanding options, restricted stock units, warrants, and the 2017 expiration of IPO-related lock-up agreements.